PALB2 and neoplasm: Overall, 28% of carriers of HR-related gene variants had a presence of HR-deficiency associated tumor mutational signature, which increased to 86% of carriers when only well-recognized HR genes (BRCA1, PALB2 and RAD51C) were included [75].